Amendments to the Specification

Please replace the paragraph [0017] at page 2 of the application as published (US2007/0202103) (the paragraph on page 4, lines 21 through 28 of the application as filed) with the following amended paragraph:

> In a particularly preferred embodiment of the first aspect of the invention, the target specific portion comprises of consists of a murine BC1 antibody, or an antibody capable of competing with the binding of a BC1 antibody to oncofoetal fibronectin or a fragment or variant thereof which retains the antigen binding specificity of the parent monoclonal antibody. Production of the murine BC1 antibody is described in EP 0 344 134 B, and it is obtainable from the hybridoma deposited at the European Collection of Animal Cell Cultures, Porton Down, UK (Accession No. 88042101).

Please replace the paragraph [0020] at page 2 of the application as published (US2007/0202103) (the paragraph on page 5, lines 8 through 15 of the application as filed) with the following amended paragraph:

> In a further preferred embodiment, the ~~BC1 antibody is~~ target-specific portion comprises a human antibody or a humanised antibody. By "humanised monoclonal antibody" we include monoclonal antibodies having at least one chain wherein the framework regions are predominantly derived from a first, acceptor monoclonal antibody of human origin and at least one complementarity-determining region (CDR) is derived from a second, donor monoclonal antibody having specificity for oncofoetal fibronectin. The donor monoclonal antibody may be of human or non-human origin, for example it may be a murine monoclonal antibody, such as BC1.